US CDC seeks more data to assess vaccine risk, extends halt on Johnson & Johnson usage
|Having stopped the usage of Johnson & Johnson’s (J&J) coronavirus (COVID-19) vaccine in all 50 US states the previous day, US Centers for Disease Control and Prevention (CDC) extends the pause on the usage of the vaccine amid a lack of more data to assess the risk.
The CDC panel concludes without a vote and plans to identify a date for the next meeting related to pausing the J&J covid-19 vaccine by Friday, which aims to reconvene in a week to 10 days.
It should, however, be noted that CDC director Dr. Rochelle Walensky said, per New York Post, “Blood clots reported in recipients of the Johnson & Johnson vaccine are “similar” to the adverse reaction linked to AstraZeneca’s shot in Europe.”
Elsewhere, Novavax to participate in University of Oxford com-cov2 study comparing mixed covid-19 vaccine combos. The study will explore heterologous regimen of covid-19 vaccines from different manufacturers.
Read: Johnson & Johnson: To proactively delay rollout of vaccine in Europe
FX reaction
Given the absence of fresh news, coupled with thin trading in Asia, global markets mostly ignore the news. However, the same signals challenge to the market sentiment and may weigh on S&P 500 Futures.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.